92 related articles for article (PubMed ID: 1674868)
1. Mechanisms involved in stimulation of insulin secretion by the hypoglycaemic alpha-adrenergic antagonist, DG-5128.
Chan SL; Stillings MR; Morgan NG
Biochem Biophys Res Commun; 1991 May; 176(3):1545-51. PubMed ID: 1674868
[TBL] [Abstract][Full Text] [Related]
2. Stimulation of insulin secretion by efaroxan may involve interaction with potassium channels.
Chan SL; Morgan NG
Eur J Pharmacol; 1990 Jan; 176(1):97-101. PubMed ID: 2178947
[TBL] [Abstract][Full Text] [Related]
3. The alpha 2-adrenoceptor antagonist efaroxan modulates K+ATP channels in insulin-secreting cells.
Chan SL; Dunne MJ; Stillings MR; Morgan NG
Eur J Pharmacol; 1991 Oct; 204(1):41-8. PubMed ID: 1687123
[TBL] [Abstract][Full Text] [Related]
4. Antagonism of the stimulatory effects of efaroxan and glibenclamide in rat pancreatic islets by the imidazoline, RX801080.
Brown CA; Chan SL; Stillings MR; Smith SA; Morgan NG
Br J Pharmacol; 1993 Nov; 110(3):1017-22. PubMed ID: 7905338
[TBL] [Abstract][Full Text] [Related]
5. Stimulation of insulin secretion by the imidazoline alpha 2-adrenoceptor antagonist efaroxan is mediated by a novel, stereoselective, binding site.
Chan SL; Brown CA; Morgan NG
Eur J Pharmacol; 1993 Jan; 230(3):375-8. PubMed ID: 8095024
[TBL] [Abstract][Full Text] [Related]
6. Control of insulin secretion by imidazolines in rat pancreatic islets.
Brown CA; Morgan NG
Biochem Soc Trans; 1993 May; 21(2):109S. PubMed ID: 8359366
[No Abstract] [Full Text] [Related]
7. The properties of imidazoline derivatives to stimulate insulin release by hamster pancreatic islets are probably due to alpha 2-adrenoceptor blockade but not to interaction with non-adrenergic idazoxan binding sites.
Lacombe CR; Viallard VP; Paris HJ
Diabete Metab; 1993; 19(4):381-6. PubMed ID: 7904946
[TBL] [Abstract][Full Text] [Related]
8. Interactions between imidazoline compounds and sulphonylureas in the regulation of insulin secretion.
Mourtada M; Brown CA; Smith SA; Piercy V; Chan SL; Morgan NG
Br J Pharmacol; 1997 Jun; 121(4):799-805. PubMed ID: 9208151
[TBL] [Abstract][Full Text] [Related]
9. In vitro stimulation of insulin release by SL 84.0418, a new alpha 2-adrenoceptor antagonist.
Jonas JC; Plant TD; Angel I; Langer SZ; Henquin JC
Eur J Pharmacol; 1994 Mar; 254(1-2):27-33. PubMed ID: 7911430
[TBL] [Abstract][Full Text] [Related]
10. Elevation of cytosolic calcium by imidazolines in mouse islets of Langerhans: implications for stimulus-response coupling of insulin release.
Shepherd RM; Hashmi MN; Kane C; Squires PE; Dunne MJ
Br J Pharmacol; 1996 Nov; 119(5):911-6. PubMed ID: 8922740
[TBL] [Abstract][Full Text] [Related]
11. Alpha-adrenoceptors and insulin release from pancreatic islets of normal and diabetic rats.
Ostenson CG; Cattaneo AG; Doxey JC; Efendic S
Am J Physiol; 1989 Sep; 257(3 Pt 1):E439-43. PubMed ID: 2571300
[TBL] [Abstract][Full Text] [Related]
12. Heterogeneous characteristics of imidazoline-induced insulin secretion.
Rustenbeck I; Leupolt L; Kowalewski R; Hasselblatt A
Naunyn Schmiedebergs Arch Pharmacol; 1999 Mar; 359(3):235-42. PubMed ID: 10208311
[TBL] [Abstract][Full Text] [Related]
13. Stimulation of insulin secretion by imidazoline compounds is not due to interaction with non-adrenoceptor idazoxan binding sites.
Brown CA; Loweth AC; Smith SA; Morgan NG
Br J Pharmacol; 1993 Feb; 108(2):312-7. PubMed ID: 8095415
[TBL] [Abstract][Full Text] [Related]
14. The imidazoline I1 receptor agonist, moxonidine, inhibits insulin secretion from isolated rat islets of Langerhans.
Tsoli E; Chan SL; Morgan NG
Eur J Pharmacol; 1995 Sep; 284(1-2):199-203. PubMed ID: 8549627
[TBL] [Abstract][Full Text] [Related]
15. Insulin releasing action of 2-[2-(4,5-dihydro-1H-imadazol-2-yl)-1-phenylethyl] pyridine dihydrochloride sesquihydrate (DG-5128), a new, orally effective hypoglycaemic agent.
Kameda K; Ono S; Koyama I; Abiko Y
Acta Endocrinol (Copenh); 1982 Mar; 99(3):410-5. PubMed ID: 6122320
[TBL] [Abstract][Full Text] [Related]
16. Evidence for two different imidazoline sites on pancreatic B cells and vascular bed in rat.
Berdeu D; Gross R; Puech R; Loubatières-Mariani MM; Bertrand G
Eur J Pharmacol; 1995 Feb; 275(1):91-8. PubMed ID: 7774667
[TBL] [Abstract][Full Text] [Related]
17. The potential antidiabetic activity of some alpha-2 adrenoceptor antagonists.
Abdel-Zaher AO; Ahmed IT; El-Koussi AD
Pharmacol Res; 2001 Nov; 44(5):397-409. PubMed ID: 11712871
[TBL] [Abstract][Full Text] [Related]
18. ATP-sensitive potassium channels and efaroxan-induced insulin release in the electrofusion-derived BRIN-BD11 beta-cell line.
Chapman JC; McClenaghan NH; Cosgrove KE; Hashmi MN; Shepherd RM; Giesberts AN; White SJ; Ammälä C; Flatt PR; Dunne MJ
Diabetes; 1999 Dec; 48(12):2349-57. PubMed ID: 10580423
[TBL] [Abstract][Full Text] [Related]
19. Sigma receptor ligands and imidazoline secretagogues mediate their insulin secretory effects by activating distinct receptor systems in isolated islets.
Chan SL; Morgan NG
Eur J Pharmacol; 1998 Jun; 350(2-3):267-72. PubMed ID: 9696417
[TBL] [Abstract][Full Text] [Related]
20. [Stimulation of insulin release and cAMP levels in isolated rat islets by the imidazoline alpha 2-adrenoceptor antagonist midaglizole: comparison with the action of the alpha 2-adrenoceptor antagonist yohimbine].
Ono S
Nihon Yakurigaku Zasshi; 1995 Mar; 105(3):137-44. PubMed ID: 7721191
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
